Predicting Visual Acuity by Using Machine Learning in Patients Treated for Neovascular Age-Related Macular Degeneration

被引:95
作者
Rohm, Markus [1 ,2 ]
Tresp, Volker [2 ]
Mueller, Michael [1 ]
Kern, Christoph [1 ]
Manakov, Ilja [1 ,2 ]
Weiss, Maximilian [1 ]
Sim, Dawn A. [3 ]
Priglinger, Siegfried [1 ]
Keane, Pearse A. [3 ]
Kortuem, Karsten [1 ,3 ]
机构
[1] Ludwig Maximilians Univ Munchen, Dept Ophthalmol, Munich, Germany
[2] Ludwig Maximilians Univ Munchen, Dept Comp Sci, Munich, Germany
[3] Moorfields Eye Hosp, London, England
关键词
INTRAVITREAL AFLIBERCEPT; DIABETIC-RETINOPATHY; RANIBIZUMAB; BEVACIZUMAB; OUTCOMES; EDEMA; PROGRESSION; TRIAL; EYE;
D O I
10.1016/j.ophtha.2017.12.034
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To predict, by using machine learning, visual acuity (VA) at 3 and 12 months in patients with neovascular age-related macular degeneration (AMD) after initial upload of 3 anti-vascular endothelial growth factor (VEGF) injections. Design: Database study. Participants: For the 3-month VA forecast, 653 patients (379 female) with 738 eyes and an average age of 74.1 years were included. The baseline VA before the first injection was 0.54 logarithm of the minimum angle of resolution (logMAR) (+/- 0.39). A total of 456 of these patients (270 female, 508 eyes, average age: 74.2 years) had sufficient follow-up data to be included for a 12-month VA prediction. The baseline VA before the first injection was 0.56 logMAR (+/- 0.42). Methods: Five different machine-learning algorithms (AdaBoost.R2, Gradient Boosting, Random Forests, Extremely Randomized Trees, and Lasso) were used to predict VA in patients with neovascular AMD after treatment with 3 anti-VEGF injections. Clinical data features came from a data warehouse (DW) containing electronic medical records (41 features, e.g., VA) and measurement features from OCT (124 features, e.g., central retinal thickness). The VA of patient eyes excluded from machine learning was predicted and compared with the ground truth, namely, the actual VA of these patients as recorded in the DW. Main Outcome Measures: Difference in logMAR VA after 3 and 12 months upload phase between prediction and ground truth as defined. Results: For the 3-month VA forecast, the difference between the prediction and ground truth was between 0.11 logMAR (5.5 letters) mean absolute error (MAE)/0.14 logMAR (7 letters) root mean square error (RMSE) and 0.18 logMAR (9 letters) MAE/0.2 logMAR (10 letters) RMSE. For the 12-month VA forecast, the difference between the prediction and ground truth was between 0.16 logMAR (8 letters) MAE/0.2 logMAR (10 letters) RMSE and 0.22 logMAR (11 letters) MAE/0.26 logMAR (13 letters) RMSE. The best performing algorithm was the Lasso protocol. Conclusions: Machine learning allowed VA to be predicted for 3 months with a comparable result to VA measurement reliability. For a forecast after 12 months of therapy, VA prediction may help to encourage patients adhering to intravitreal therapy. (C) 2018 by the American Academy of Ophthalmology
引用
收藏
页码:1028 / 1036
页数:9
相关论文
共 42 条
[11]   Quantitative SD-OCT Imaging Biomarkers as Indicators of Age-Related Macular Degeneration Progression [J].
de Sisternes, Luis ;
Simon, Noah ;
Tibshirani, Robert ;
Leng, Theodore ;
Rubin, Daniel L. .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (11) :7093-7103
[12]   Bivariate Analysis of Age-Related Macular Degeneration Progression Using Genetic Risk Scores [J].
Ding, Ying ;
Liu, Yi ;
Yan, Qi ;
Fritsche, Lars G. ;
Cook, Richard J. ;
Clemons, Traci ;
Ratnapriya, Rinki ;
Klein, Michael L. ;
Abecasis, Goncalo R. ;
Swaroop, Anand ;
Chew, Emily Y. ;
Weeks, Daniel E. ;
Chen, Wei .
GENETICS, 2017, 206 (01) :119-133
[13]  
Drucker H., ICML1997, V97
[14]   Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer [J].
Ferrara, N ;
Hillan, KJ ;
Gerber, HP ;
Novotny, W .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (05) :391-400
[15]   Introduction to "This is Watson" [J].
Ferrucci, D. A. .
IBM JOURNAL OF RESEARCH AND DEVELOPMENT, 2012, 56 (3-4)
[16]   Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - A noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany [J].
Finger, Robert P. ;
Wiedemann, Peter ;
Blumhagen, Francisca ;
Pohl, Karin ;
Holz, Frank G. .
ACTA OPHTHALMOLOGICA, 2013, 91 (06) :540-546
[17]   Extremely randomized trees [J].
Geurts, P ;
Ernst, D ;
Wehenkel, L .
MACHINE LEARNING, 2006, 63 (01) :3-42
[18]   Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs [J].
Gulshan, Varun ;
Peng, Lily ;
Coram, Marc ;
Stumpe, Martin C. ;
Wu, Derek ;
Narayanaswamy, Arunachalam ;
Venugopalan, Subhashini ;
Widner, Kasumi ;
Madams, Tom ;
Cuadros, Jorge ;
Kim, Ramasamy ;
Raman, Rajiv ;
Nelson, Philip C. ;
Mega, Jessica L. ;
Webster, R. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (22) :2402-2410
[19]   MICROANEURYSM FORMATION RATE AS A PREDICTIVE MARKER FOR PROGRESSION TO CLINICALLY SIGNIFICANT MACULAR EDEMA IN NONPROLIFERATIVE DIABETIC RETINOPATHY [J].
Haritoglou, Christos ;
Kernt, Marcus ;
Neubauer, Aljoscha ;
Gerss, Joachim ;
Oliveira, Carlos Manta ;
Kampik, Anselm ;
Ulbig, Michael .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2014, 34 (01) :157-164
[20]   Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration [J].
Heier, Jeffrey S. ;
Brown, David M. ;
Chong, Victor ;
Korobelnik, Jean-Francois ;
Kaiser, Peter K. ;
Quan Dong Nguyen ;
Kirchhof, Bernd ;
Ho, Allen ;
Ogura, Yuichiro ;
Yancopoulos, George D. ;
Stahl, Neil ;
Vitti, Robert ;
Berliner, Alyson J. ;
Soo, Yuhwen ;
Anderesi, Majid ;
Groetzbach, Georg ;
Sommerauer, Bernd ;
Sandbrink, Rupert ;
Simader, Christian ;
Schmidt-Erfurth, Ursula .
OPHTHALMOLOGY, 2012, 119 (12) :2537-2548